Literature DB >> 2164226

Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.

P Seckinger1, J H Zhang, B Hauptmann, J M Dayer.   

Abstract

Previous studies have shown that urine of febrile patients contains a tumor necrosis factor alpha inhibiting activity (TNF-alpha Inh) when tested in a cytotoxicity assay using the tumor necrosis factor alpha (TNF-alpha)-susceptible cell line L929. In the present study, we investigated the relationship between the TNF-alpha Inh and a potential soluble form of the receptor, as the former has been shown to block TNF-alpha activities by binding to the ligand. We demonstrate that human TNF-alpha is affected to a greater extent than is murine TNF-alpha. This species specificity of the inhibitor correlates with the binding studies of TNF receptor interactions already reported. We raised a polyclonal antibody to TNF-alpha Inh that neutralizes its activity and does not recognize TNF-alpha. Solubilized cross-linked 125I-labeled TNF-alpha receptor complex could be immunoprecipitated by using either anti-TNF-alpha or anti-TNF-alpha Inh antibody, suggesting immunological cross-reactivity between the receptor and the inhibitor. By using fluorescein isothiocyanate-coupled TNF-alpha, it was possible to visualize by fluorescence-activated cell sorter analysis the TNF-alpha receptor on phytohemagglutinin/interleukin 2-activated T cells. A similar increase of immunofluorescence intensity of the activated T cells was observed by using anti-TNF-alpha Inh antibody revealed with a fluorescein isothiocyanate-coupled goat anti-rabbit IgG1 conjugate, suggesting that the TNF-alpha Inh is also expressed as a membrane protein. Taken together, our results suggest that the TNF-alpha Inh originally described might be a soluble form of the TNF receptor itself.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164226      PMCID: PMC54287          DOI: 10.1073/pnas.87.13.5188

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha.

Authors:  S M Kramer; B B Aggarwal; T E Eessalu; S M McCabe; B L Ferraiolo; I S Figari; M A Palladino
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

Review 2.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Structure of tumour necrosis factor by X-ray solution scattering and preliminary studies by single crystal X-ray diffraction.

Authors:  A Lewit-Bentley; R Fourme; R Kahn; T Prangé; P Vachette; J Tavernier; G Hauquier; W Niers
Journal:  J Mol Biol       Date:  1988-01-20       Impact factor: 5.469

4.  Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937.

Authors:  G B Stauber; B B Aggarwal
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

5.  Human tumor necrosis factor-alpha receptor. Purification by immunoaffinity chromatography and initial characterization.

Authors:  G B Stauber; R A Aiyer; B B Aggarwal
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

6.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

7.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

Authors:  H Engelmann; D Aderka; M Rubinstein; D Rotman; D Wallach
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

8.  Isolation and characterization of a tumor necrosis factor binding protein from urine.

Authors:  I Olsson; M Lantz; E Nilsson; C Peetre; H Thysell; A Grubb; G Adolf
Journal:  Eur J Haematol       Date:  1989-03       Impact factor: 2.997

9.  Structure of tumour necrosis factor.

Authors:  E Y Jones; D I Stuart; N P Walker
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

10.  A human inhibitor of tumor necrosis factor alpha.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  33 in total

Review 1.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

Review 2.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

3.  Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody.

Authors:  J Jansen; T van der Poll; M Levi; H ten Cate; H Gallati; J W ten Cate; S J van Deventer
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

Review 4.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

5.  In vitro and in vivo induction of tumor necrosis factor alpha by Borrelia burgdorferi.

Authors:  D L Defosse; R C Johnson
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 6.  Cytokines in rheumatoid arthritis.

Authors:  F A Houssiau
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

7.  Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions.

Authors:  K E Norman; T J Williams; M Feldmann; A G Rossi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Actinomycin D upregulates lipopolysaccharide induction of macrophage procoagulant expression and tumour necrosis factor-alpha production.

Authors:  H R Wheeler; E J Rockett; I Clark; C L Geczy
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 9.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

10.  Variables that affect assays for plasma cytokines and soluble activation markers.

Authors:  N Aziz; P Nishanian; R Mitsuyasu; R Detels; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1999-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.